BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Scientists find twisting magnetic waves on the sun. Could this help solve a huge solar mystery? - 2Step by step instructions to Lessen Your Gamble of Creating Cellular breakdown in the lungs
- 3Well known Worldwide Caf\u00e9s to Experience
- 4How effective is the flu shot this year? New report shows promising results
- 5Flourishing in a Remote Workplace: Individual Techniques
- Pick Your Number one sort of blossom
- Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
- Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
- Polls open in tense Uganda election amid widespread delays
- Why most Jewish Israelis back the death penalty for terrorists
- 'A perfect storm': Airlines cut flights and increase airfares as jet fuel price spikes
- Building an Individual Brand: Illustrations from Powerhouses
- ‘Aid for Ukraine’ pierogi fundraiser event
- Hundreds show fascist salute at rally in Rome in annual ritual
